Figma Shares Indicated To Open $105/$110
In a recent 8-K filing with the Securities and Exchange Commission, Cencora, Inc., a Delaware-based company in the wholesale drug industry and a prominent player in Healthcare Providers & Services with over $300 billion in annual revenue, reported the outcomes of its Annual Meeting held on March 6, 2025. According to InvestingPro data, the company’s stock is trading near its 52-week high, reflecting strong market confidence. InvestingPro analysis reveals 14 key investment tips for Cencora, including insights about its market position and financial stability. Shareholders voted on several key issues, including the election of directors and executive compensation.
The election results confirmed the appointment of all nominated board members. Ornella Barra, Werner Baumann, Frank K. Clyburn, Steven H. Collis, D. Mark Durcan, Lon R. Greenberg, Lorence H. Kim, M.D., Robert P. Mauch, Redonda G. Miller, M.D., Dennis M. Nally, and Lauren M. Tyler were elected with a majority of votes in favor, and the number of abstentions and broker non-votes were relatively low.
Shareholders also cast their votes on the advisory resolution to approve the compensation of the company’s named executive officers. The resolution passed with 156,885,713 votes for, 12,269,867 votes against, and 187,486 abstentions. Broker non-votes totaled 9,542,398.
Additionally, the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year 2025 was approved by the shareholders. The accounting firm received 166,297,099 votes in favor, 12,410,706 votes against, and 177,659 abstentions.
No other items were submitted for shareholder action at the Annual Meeting beyond what was described in the definitive proxy statement filed on January 23, 2025.
This report was signed on behalf of the registrant by Elizabeth S. Campbell, Executive Vice President and Chief Legal Officer of Cencora, Inc., on March 10, 2025. The information provided in this article is based on a press release statement.
In other recent news, Cencora, Inc. has reported notable developments that are of interest to investors. The company has completed the acquisition of Retina Consultants of America for $4.4 billion, which led to an upward revision of its fiscal year 2025 adjusted earnings per share (EPS) guidance. The new EPS range is set between $15.15 and $15.45, an increase from the previous estimate of $14.80 to $15.10. This acquisition is expected to bolster Cencora’s position in specialty medical services and enhance its management services organization solutions.
Additionally, Leerink Partners has raised Cencora’s stock price target to $301 from $287, maintaining an Outperform rating. This adjustment follows Cencora’s impressive first-quarter fiscal year 2025 results, which exceeded expectations and resulted in guidance upgrades. The firm’s robust performance in the U.S. Healthcare sector continues to drive positive analyst sentiment.
In other corporate news, Cencora announced the upcoming retirements of two long-standing board members, Richard W. Gochnauer and Kathleen W. Hyle, as disclosed in a recent SEC filing. Their retirement will take effect at the next Annual Meeting of Stockholders in March 2025, reducing the board from 13 to 11 members. These developments reflect Cencora’s ongoing strategic maneuvers and leadership transitions as it navigates the competitive pharmaceutical distribution landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.